December 2018 - Clinical trial listings - geography, conditions, companies -

Clinical Trials for Claritin-d 24 Hour

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00550550	Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	Phase 3	The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma.
NCT00562159	Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	Phase 3	This purpose of this study is to determine the efficacy and safety of a grass sublingual (under-the-tongue) tablet.
NCT00762983	Observation of Use of Claritin (Loratadine) Tablet, RediTabs, and Dry Syrup in Children (Study P05834)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	N/A	The purpose of this study is to collect information on unexpected adverse reactions (ADRs), how often ADRs occur, and factors that can affect the safety and effectiveness of Claritin (loratadine) when used in children. Patients will be observed while they are taking Claritin, and ADRs and symptom scores will be recorded. At the end of treatment, improvement in symptoms will be recorded. Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.
NCT00776217	Bioequivalence Study on Loratadine Orally Disintegrating Tablets 10 mg Under Fasting Conditions	Completed	Ranbaxy Laboratories Limited	N/A	To compare the single-dose oral bioavailability of loratadine 10 mg orally disintegrating tablets of Ohm Laboratories (a subsidiary of Ranbaxy Pharmaceuticals Inc., USA) with Claritin® Reditabs® (containing loratadine 10 mg) of Schering-Plough Healthcare Product Inc., USA in healthy, adult, human male subjects under fasting condition.
NCT00776282	Bioequivalence Study of Loratadine Orally Disintegrating Tablets 10 mg Under Fed Conditions	Completed	Ranbaxy Laboratories Limited	N/A	To compare the single-dose oral bioavailability of loratadine 10 mg orally disintegrating tablets of Ohm Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals, Inc. USA) with Claritin® Reditabs® (containing loratadine 10 mg) of Schering-Plough Healthcare Product Inc., USA in healthy, adult, human male subjects under fed condition.
Trial ID	Title	Status	Sponsor	Phase	Summary